Aller au contenu principal
Profil bibliographique

J. Daniel Pennington

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

3Publications signalées
3Citations signalées
3Affiliations récentes

Les institutions déclarées

Les domaines associés

Prostate Cancer Diagnosis and TreatmentAdvanced Radiotherapy TechniquesHead and Neck Cancer StudiesLung Cancer Treatments and MutationsProstate Cancer Treatment and Research

Les publications récentes

Accès ouvert 2026 article OpenAlex

Stereotactic Body Radiotherapy vs Moderately Hypofractionated IMRT for Localized Intermediate-Risk Prostate Cancer

Rodney J. Ellis, Stephanie L. Pugh, James B. Yu, Felix Y. Feng et autres

Importance: The treatment of prostate cancer with radiotherapy is evolving. How quickly radiotherapy can be delivered, and the relative risks and benefits of such a treatment, is of significant public interest. Objective: To determine whether stereotactic body radiotherapy (SBRT) was superior to …

us, ca, ie (code pays fourni par la source)

2 citations JAMA
Accès ouvert 2026 article OpenAlex

A Multimodal Artificial Intelligence Model to Guide Use of Whole-Pelvic Radiation Therapy in Patients with Localized Prostate Cancer: Exploratory Analysis of RTOG 9413

Mutlay Sayan, Huei-Chung Huang, Erin L. Stewart, Timothy N. Showalter et autres

Background/Objectives: This study explored whether a multimodal artificial intelligence (MMAI) model integrating digitized histopathology and clinical features can identify prostate cancer patients who may benefit from neoadjuvant hormonal therapy (NHT) and whole-pelvic radiotherapy (WPRT). Methods: This secondary analysis of NRG/RTOG 9413 included …

us, gb (code pays fourni par la source)

0 citations Cancers
Accès ouvert 2026 article OpenAlex

The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial

Joanne Barnes Weidhaas, J. Harris, Maura L. Gillison, Dukagjin M. Blakaj et autres

PURPOSE: NRG/RTOG 1016 was a phase III noninferiority trial comparing IMRT + cisplatin versus IMRT + cetuximab for human papillomavirus-positive oropharyngeal squamous cell cancer (HPV+ OPSCC). A germline mutation (the KRAS-variant) previously identified patients with improved outcomes to radiation + cetuximab + …

us, ca (code pays fourni par la source)

1 citation Cancer Research Communications

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.